Bionano Genomics, Inc.

Equities

BNGO

US09075F3055

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 21:00:00 17/07/2024 BST			5-day change	1st Jan Change
0.6645 ^USD	+0.80%		+2.61%	-64.84%

07-08	Bionano Genomics Raises $10 Million From Direct Offering	MT
07-05	Sector Update: Health Care Stocks Advance Late Afternoon	MT

BIONANO GENOMICS, INC : Other Events (form 8-K)

January 04, 2021 at 11:21 am

Item 8.01 Other Events.

On December 31, 2020, Bionano Genomics, Inc. (the "Company") obtained a waiver from Innovatus Life Sciences Lending Fund I, LP ("Innovatus") of its previously disclosed noncompliance, as of September 30, 2020, with a revenue covenant contained in the Loan and Security Agreement, dated March 14, 2019, among the Company, Innovatus and East West Bank, as amended. --------------------------------------------------------------------------------

Latest news about Bionano Genomics, Inc.

Bionano Genomics Raises $10 Million From Direct Offering	07-08	MT
Sector Update: Health Care Stocks Advance Late Afternoon	07-05	MT
Bionano Genomics to Sell Shares in Direct Offering	07-05	MT
Bionano Genomics Says Revvity to Commercialize VIA Software	06-20	MT
Bionano Genomics Raises $18 Million From Private Debentures Placement	05-28	MT
Bionano Genomics, Inc. announced that it has received $18 million in funding	05-23	CI
Bionano Genomics, Inc. Announces Significant Upgrades to its Suite of Computational Tools for Comprehensive Cancer Analysis	05-09	CI
Transcript : Bionano Genomics, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Bionano Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Bionano Genomics, Inc. Provides Revenue Guidance for the Second Quarter of 2024 and Reiterated Revenue Guidance for the Year 2024	05-08	CI
Bionano Genomics, Hangzhou Diagens Biotechnology to Commercialize Cytogenetic Workflow for Reproductive Health	04-17	MT
Bionano Genomics, Inc. and Hangzhou Diagens Biotechnology Co., Ltd. Sign Partnership to Commercialize the First Ever Clinical Cytogenetic Analysis That Combines OGM and Artificial Intelligence	04-17	CI
Bionano Announces Publication Showing That Ogm Identifies Genetic Aberrations in Sarcoma Samples That May Lead to Improved Diagnosis But Were Missed by Classical Cytogenetics	04-03	CI
Bionano Genomics, Inc. Announces Nine Poster Presentations and Introduces New High Throughput Stratys System at American Association for Cancer Research Annual Meeting	04-02	CI
Bionano Genomics, Inc. Announces Publication of Breast Cancer Study Showing the Number of SVs Detected with OGM May be Related to Prognosis, Tumor Progression and Chemotherapy Resistance	03-19	CI
Scotiabank Trims Price Target on Bionano Genomics to $6 From $7, Maintains Sector Outperform Rating	03-07	MT
Bionano Genomics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Transcript : Bionano Genomics, Inc., Q4 2023 Earnings Call, Mar 05, 2024	03-05
Bionano Genomics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-05	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024	03-05	CI
Bionano Genomics, Inc. announced that it has received $35 million in funding	02-26	CI
Bionano Genomics, Inc. Announces Publication of A Study That Applied Ogm to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer	01-25	CI
Bionano Announces Full Commercial Release of the Stratys?? System for High Throughput Optical Genome Mapping	01-23	CI
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care in Genetic Disease Testing	01-11	CI
Bionano Genomics, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	01-08	CI

Chart Bionano Genomics, Inc.

Duration

Period

More charts

Company Profile

Bionano Genomics, Inc. is a genomics company. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. Through Lineagen, Inc., the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Sector

Advanced Medical Equipment & Technology

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Bionano Genomics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6645 USD

Average target price

4.933 USD

Spread / Average Target

+642.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
BIONANO GENOMICS, INC.	-64.84%	53.27M
THERMO FISHER SCIENTIFIC	+4.57%	212B
DANAHER CORPORATION	+8.61%	187B
INTUITIVE SURGICAL, INC.	+26.34%	155B
BOSTON SCIENTIFIC CORPORATION	+33.90%	115B
SIEMENS HEALTHINEERS AG	+2.17%	65.5B
EDWARDS LIFESCIENCES CORPORATION	+14.50%	52.87B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-3.30%	45.25B
AGILENT TECHNOLOGIES, INC.	-3.98%	39.7B
GE HEALTHCARE TECHNOLOGIES INC.	+6.66%	37.72B

Other Advanced Medical Equipment & Technology